{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:57:41Z","timestamp":1763755061735,"version":"3.45.0"},"reference-count":19,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1188\/19.cjon.355-358","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T10:15:44Z","timestamp":1563531344000},"page":"355-358","source":"Crossref","is-referenced-by-count":2,"title":["Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma"],"prefix":"10.1188","volume":"23","author":[{"given":"Jessica","family":"Latchman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Guastella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Tofthagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Achkar, T., & Tarhini, A.A. (2017). The use of immunotherapy in the treatment of melanoma. Journal of Hematology and Oncology, 10, 88. https:\/\/doi.org\/10.1186\/s13045-017-0458-3","DOI":"10.1186\/s13045-017-0458-3"},{"key":"2","unstructured":"American Cancer Society. (2019). Cancer facts and figures, 2019. Retrieved from https:\/\/bit.ly\/2FlG9Xx"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Astaras, C., de Micheli, R., Moura, B., Hundsberger, T., & Hottinger, A.F. (2018). Neurological adverse events associated with immune checkpoint inhibitors: Diagnosis and management. Current Neurology and Neuroscience Reports, 18, 3. https:\/\/doi.org\/10.1007\/s11910-018-0810-1","DOI":"10.1007\/s11910-018-0810-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bayer, V., Amaya, B., Baniewicz, D., Callahan, C., Marsch, L., & McCoy, A.S. (2017). Cancer immunotherapy: An evidence-based overview and implications for practice. Clinical Journal of Oncology Nursing, 21(Suppl.), 13\u201321.","DOI":"10.1188\/17.CJON.S2.13-21"},{"key":"5","unstructured":"Bickley, L.S. (2017). Bates\u2019 pocket guide to physical examination and history taking (8th ed.). Philadelphia, PA: Wolters Kluwer."},{"key":"6","doi-asserted-by":"crossref","unstructured":"Bompaire, F., Mateus, C., Taillia, H., De Greslan, T., Lahutte, M., Sallansonnet-Froment, M., . . . Ricard, D. (2012). Severe meningo-radiculo-neuritis associated with ipilimumab. Investigational New Drugs, 30, 2407\u20132410. https:\/\/doi.org\/10.1007\/s10637-011-9787-1","DOI":"10.1007\/s10637-011-9787-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Carlo, M.I., Voss, M.H., & Motzer, R.J. (2016). Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature Reviews Urology, 13, 420\u2013431. https:\/\/doi.org\/10.1038\/nrurol.2016.103","DOI":"10.1038\/nrurol.2016.103"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Cioroiu, C., & Weimer, L.H. (2017). Update on chemotherapy-induced peripheral neuropathy. Current Neurology and Neuroscience Reports, 17, 47. https:\/\/doi.org\/10.1007\/s11910-017-0757-7","DOI":"10.1007\/s11910-017-0757-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Dalakas, M.C. (2018). Neurological complications of immune checkpoint inhibitors: What happens when you \u2018take the brakes off\u2019 the immune system. Therapeutic Advances in Neurological Disorders, 11, 1756286418799864. https:\/\/doi.org\/10.1177\/1756286418799864","DOI":"10.1177\/1756286418799864"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gaudy-Marqueste, C., Monestier, S., Franques, J., Cantais, E., Richard, M.-A., & Grob, J.-J. (2013). A severe case of ipilimumab-induced Guillain-Barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: A differential diagnosis for ipilimumab-induced colitis. Journal of Immunotherapy, 36, 77\u201378. https:\/\/doi.org\/10.1097\/CJI.0b013e31827807dd","DOI":"10.1097\/CJI.0b013e31827807dd"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Gonzalez, N.L., Puwanant, A., Lu, A., Marks, S.M., & \u017divkovi\u0107, S.A. (2017). Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Neuromuscular Disorders, 27, 266\u2013268.","DOI":"10.1016\/j.nmd.2017.01.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Gutzmer, R., Koop, A., Meier, F., Hassel, J.C., Terheyden, P., Zimmer, L., . . . K\u00e4hler, K.C. (2017). Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. European Journal of Cancer, 75, 24\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.038","DOI":"10.1016\/j.ejca.2016.12.038"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Haanen, J.B.A.G., Carbonnel, F., Robert, C., Kerr, K.M., Peters, S., Larkin, J., & Jordan, K. (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28(Suppl. 4), iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","DOI":"10.1093\/annonc\/mdx225"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C.L., . . . Wolchok, J.D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, 19, 1480\u20131492. https:\/\/doi.org\/10.1016\/s1470-2045(18)30700-9","DOI":"10.1016\/S1470-2045(18)30700-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Hottinger, A.F. (2016). Neurologic complications of immune checkpoint inhibitors. Current Opinion in Neurology, 29, 806\u2013812. https:\/\/doi.org\/10.1097\/wco.0000000000000391","DOI":"10.1097\/WCO.0000000000000391"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Jinnur, P., & Lim, K.G. (2015). Severe acute orthopnea: Ipilimumab-induced bilateral phrenic nerve neuropathy. Lung, 193, 611\u2013613. https:\/\/doi.org\/10.1007\/s00408-015-9716-8","DOI":"10.1007\/s00408-015-9716-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Lee, C.-S., Thomas, C.M., & Ng, K.E. (2017). An overview of the changing landscape of treatment for advanced melanoma. Pharmacotherapy, 37, 319\u2013333.","DOI":"10.1002\/phar.1895"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Spain, L., Walls, G., Julve, M., O\u2019Meara, K., Schmid, T., Kalaitzaki, E.,. . . Larkin, J. (2017). Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. Annals of Oncology, 28, 377\u2013385.","DOI":"10.1093\/annonc\/mdw558"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Stone, J.B., & DeAngelis, L.M. (2016). Cancer-treatment-induced neurotoxicity\u2014Focus on newer treatments. Nature Reviews Clinical Oncology, 13, 92\u2013105.","DOI":"10.1038\/nrclinonc.2015.152"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/23\/4\/neurologic-complications-effects-ipilimumab-and-nivolumab-therapy-patients-metastatic","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:45Z","timestamp":1763754645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/23\/4\/neurologic-complications-effects-ipilimumab-and-nivolumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1188\/19.cjon.355-358","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}